Psychoactive substances are associated with the idea of drugs with high addictive liability, affecting mental states, cognition, emotion and motor behavior. However these substances can modify synaptic transmission and help to disclose some mechanisms underlying alterations in brain processing and pathophysiology of motor disease. Hence, the 'bright side' of e cannabinoid-based drugs must be thoroughly examined to be identified within the latter framework. Areas covered: We will analyze the preclinical and clinical evidence of cannabinoid-based drugs, discussing their therapeutic value in basal ganglia motor disorders such as Parkinson's disease and Huntington disease. Expert commentary: Despite the knowledge acquired in the last years, the therapeutic potential of cannabinoid-based drugs should be further tested by novel routes of investigation. This should be focused on the role of cannabinoid signaling system in mitochondrial function as well as on the physical and functional interaction with other key receptorial targets belonging to this network.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17512433.2016.1209111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.
Pharmacol Ther
January 2025
Xi'an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research, Shaanxi University of Science & Technology, Xi'an 710021, China; School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an 710021, China. Electronic address:
G protein-coupled receptors (GPCRs) adopt conformational states that activate or inhibit distinct signaling pathways, including those mediated by G proteins or β-arrestins. Biased signaling through GPCRs may offer a promising strategy to enhance therapeutic efficacy while reducing adverse effects. Cannabinoid receptor 1 (CB1), a key GPCR in the endocannabinoid system, presents therapeutic potential for conditions such as pain, anxiety, cognitive impairment, psychiatric disorders, and metabolic diseases.
View Article and Find Full Text PDFResearch and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.
Pharmaceuticals (Basel)
December 2024
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, Brazil.
Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness.
View Article and Find Full Text PDF: From Plants to Humans.
Int J Mol Sci
December 2024
Research Centre for Cereal and Industrial Crops, Council for Agricultural Research and Economics (CREA), S.S. 673, Meters 25200, 71122 Foggia, Italy.
This Special Issue aims to highlight some of the most recent developments in the study of by collecting contributions that range from studies on the crop and its interaction with the environment and pathogens to the pharmaceutical applications of cannabinoid-based drugs, also including the health risks associated with the consumption of .
View Article and Find Full Text PDFCytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells.
Front Pharmacol
November 2024
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Introduction: Cannabinoids are reported to suppress the growth of ovarian cancer cells, but it is unclear whether structural modifications can improve their cytotoxic effects.
Methods: Herein, an investigation into the antiproliferative effects of natural cannabinoids on human ovarian cancer Caov-3 cells identified cannabidiol (CBD) as the most promising cannabinoid. Furthermore, chemical modifications of CBD yielded a group of derivatives with enhanced cytotoxicity in Caov-3 cells.
Improving the Biopharmaceutical Properties of Cannabinoids in Glioblastoma Multiforme Therapy With Nanotechnology: A Drug Delivery Perspective.
Drug Dev Res
December 2024
Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Article Synopsis
- Glioblastoma multiforme (GBM) is a common and aggressive brain tumor, making traditional treatments like surgery and chemotherapy less effective due to its rapid growth and unique biology.
- Cannabinoids show promise as anti-GBM agents due to their antiangiogenic and antiproliferative properties, but their effectiveness is limited by their poor solubility and bioavailability.
- This study explores the use of nanocarriers to enhance the delivery and efficacy of cannabinoids in GBM therapy, potentially improving treatment outcomes by enabling better passage across the blood-brain barrier and supporting controlled release of the drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!